Management of recurrent epistaxis in patients on anticoagulant therapy is a challenging problem. In this article, we report our experience concerning the use of bivalve septal teflon splint (BSTS) for the treatment of recurrent mild epistaxis in a group of patients who underwent anticoagulant therapy after cardiac valve surgery. The study included 18 patients whose epistaxes recurred despite standard methods such as local pressure, vasoconstrictors, sedation, packing or cauterization. BSTS was sutured on the both sides of the nasal septum and held in place during one month. Epistaxis was controlled in all of the patients. We believe that the use of BSTS is an effective, easily applied, non-traumatic, well-tolerated additional method for the treatment of recurrent mild epistaxis in patients undergoing anticoagulant therapy, when other conventional treatments fail. Further controlled studies with larger groups are warranted in order to further evaluate this method.
Download full-text PDF |
Source |
---|
J Cardiovasc Electrophysiol
January 2025
Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, UK.
Math Biosci Eng
December 2024
Laboratory of Optimization, Design, and Advanced Control, School of Chemical Engineering, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
In the pursuit of personalized medicine, there is a growing demand for computational models with parameters that are easily obtainable to accelerate the development of potential solutions. Blood tests, owing to their affordability, accessibility, and routine use in healthcare, offer valuable biomarkers for assessing hemostatic balance in thrombotic and bleeding disorders. Incorporating these biomarkers into computational models of blood coagulation is crucial for creating patient-specific models, which allow for the analysis of the influence of these biomarkers on clot formation.
View Article and Find Full Text PDFZhonghua Yi Xue Za Zhi
January 2025
Shanghai Key Laboratory of Kidney and Blood Purification, Shanghai Medical Center of Kidney, Shanghai200032, China.
To investigate anticoagulation effects of nafamostat mesylate(NM) in sustained low-efficiency dialysis (SLED) and its relevant factors. Critically ill patients with kidney disease who were admitted to Zhongshan Hospital Affiliated to Fudan University and underwent SLED treatment from May to August 2024 were retrospectively included. Baseline clinical data were collected, and the activated partial thromboplastin time (APTT) and activated clotting time (ACT) were measured at the arterial end, before the filter, and at the venous end two hours post-NM anticoagulation treatment.
View Article and Find Full Text PDFInt J Surg
December 2024
Institute of Clinical Medicine, University of Oslo.
Background: Acute type A aortic dissection (ATAAD) has a high mortality, and acute aortic repair is the only curative treatment. In patients treated with factor Xa (FXa) inhibitors, the risk of severe disease-related complications such as cardiac tamponade and hemodynamic shock must be balanced against the potential for severe perioperative bleeding. The aim was to study intraoperative changes in plasma levels of the FXa inhibitor apixaban when using hemoadsorption during acute thoracic aortic repair.
View Article and Find Full Text PDFBMJ Open
December 2024
Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetric & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China
Introduction: Compared with the guideline-recommended use of low-molecular weight heparin (LMWH) for 28 days to prevent venous thromboembolism (VTE) after cytoreductive surgery, oral rivaroxaban avoids the pain and inconvenience of daily injections and reduces medical expenses. The proposed randomised controlled trial (RCT) aims to compare the efficacy and safety of rivaroxaban and enoxaparin in preventing VTE in patients after surgery for gynaecological malignancies and to provide a reference for clinical medication prevention.
Methods And Analysis: This is a single-centre, randomised, controlled, open-label and assessor-blind clinical trial.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!